Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Êîñìåòîëîãèÿ-äåðìàòîëîãèÿ

Êîñìåòîëîãèÿ-äåðìàòîëîãèÿ Ôîðóìû: ×àñòî çàäàâàåìûå âîïðîñû, Ôîðóì äëÿ âðà÷åé, Àëîïåöèÿ, Ãåðïåñ - äèàãíîñòèêà è ëå÷åíèå

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 28.12.2004, 17:55
Kostea Kostea âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2004
Ñîîáùåíèé: 6
Kostea *
Unhappy SOS

Âîò òàêîè ó ìåíÿ âàïðîñ ê âàì :
Ó ìåíÿ ïðîáëåìà : ìíîãî ïðûùåé íà ëèöå è íà ñïèíå. Íàøëè ñòàôèëîêîê åïèäåðìèñ, íó è àêíåÿ âóëãàðèñ ! Áûë ó ìíîãèõ äåðìàòîëîãîâ ( ïðèìåðíà 6..7 ) è ó êàæäîãî ñâî¸ ìíåíèå: îäèí ãîâîðèò ÷òî àíòèáèîòèêè íàäî, äðóãîè ãîâîðèò ÷òî àíòè-âàêöèíó íàäî, òðåòúé ñêàçàë ÷òî ÓÔÎ íàäî ( íî ìíå åøå 14 ëåò ), è òàê äàëåå.. ïðîáîâàë ÂѨ â òå÷åíèå ãîäà, íî íå ïîìîãëî..
Ñåãîäíÿ áûë ó äîêòîðà è îí ñêàçàë ÷òî ýòî ôèíàëúíàÿ ôàçà è ïîìî÷ú ìíå ìîæåò òîëúêî ÐÎÀÊÓÒÀÍ ( ROACUTAN ), íî ÿ ïîíåë ÷òî ìîãóò áûòè ïîñëåäñòâúÿ...
Ìîæåò åñòè äðóãîè ñïîñîá ëå÷åíèÿ ?
Çàðàíåå ñïàñèáî..
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 28.12.2004, 23:54
Dr.Strebkov Dr.Strebkov âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 13.07.2002
Ãîðîä: ð.Áåëàðóñü
Ñîîáùåíèé: 203
Dr.Strebkov ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
À ÷åì Âû óæå ëå÷èëèñü?
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 29.12.2004, 16:47
Kostea Kostea âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2004
Ñîîáùåíèé: 6
Kostea *
Ïåðâûé äîêòîð ñêàçàë ÷òî ÓÔÎ(óëüòðàôèîëåòîâîå .. ) íàäî äåëàòü, íî ïàñêîëèêó ìíå 14 ëåò, ÓÔÎ íå ñäåëàëü.
Ïîñëå ýòîãî ñäåëàë àíòèáèîòèêîãðàìó è íà÷åë àíòèáèîòèêè ïðèíèìàòü ( doxyciclin, cefazolin(2 ðàçà), ciprofloxacin ) è òàê ïðèíèìàë èõ ïî 10-14 äíåè. ÍÅ ÏÎÌÎÃËÎ !
Äðóãîè äîêòîð ñêàçàë ÷òî àíòè-âàêöèíà ïîìîæåò 100 %, íî ïîñëå îäíîãî êóðñà åôåêò áûë 0 !
Íå äàâíî ñäåëàë àíàëèç ÷òîáû ïîñìîòðåòü Èììóííóþ Ñèñòåìó è
Èññëåäîâàíèÿ íà Ãîðìîíû (ÈÔÀ):
Èììóííàÿ Ñèñòåìà

Ðåçóëüòàò
Íîðìà
Èììóíîãëîáóëèí À (ã/ë)
4.1
1.2-1.8
Èììóíîãëîáóëèí Ì (ã/ë)
2.61
0.6-1
Èììóíîãëîáóëèí G (ã/ë)
22.3
9.1-13.1
Èììóíîãëîáóëèí Å (ã/ë)
30.0
25-100

Èññëåäîâàíèÿ íà Ãîðìîíû
Ïðîëàêòèí
799
Òåñòîñòåðîí
1.6
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 29.12.2004, 19:31
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,508
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,708 ðàç(à) çà 32,781 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ãèïåðïðîëàêòèíåìèÿ ÍÅ ÿâëÿåòñÿ ïðè÷èíîé àêíå. Êëèíè÷åñêèé ñìûñë ïîâûøåííîãî óðîâíÿ ïðîëàêòèíà íå èçâåñòåí, ïîñêîëüêó ì.á. ò.í. áèã- ïðîëàêòèíåìèÿ( áèîõèìè÷åñêèé âàðèàíò, íå ÿâëÿþùèéñÿ ìåäèöèíñêîé ïðîáëåìîé)
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 29.12.2004, 23:28
Dr.Strebkov Dr.Strebkov âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 13.07.2002
Ãîðîä: ð.Áåëàðóñü
Ñîîáùåíèé: 203
Dr.Strebkov ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Êàêîå ïîëó÷àëè íàðóæíîå ëå÷åíèå è êàê äîëãî?
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 31.01.2005, 20:00
Kostea Kostea âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2004
Ñîîáùåíèé: 6
Kostea *
// ìîè îòåö //


Ïèøó âàì ñ íàäåæäîé íà Âàø îïûò è ïîìîùü. Ìîåìó ñûíó ïî÷òè 15 ëåò è âîò óæå ïî÷òè ãîä ìû ëå÷èì è íå ìîæåì èçáàâèòüñÿ îò Acneea Vulgaris (ñîãë. äèàãíîçó) êîòîðàÿ ðàñïîñòðàíèëàñü ïîëíîñòüþ íà ëèöî, ñïèíó è óæå ðóêè, ôîðìèðóÿ ïîäêîæíûå, ñðàâíèòåëüíî ãëóáîêèå (íå ôóðóíêóëû) ãíîéíè÷êè/ãíîéíûå îáðàçîâàíèÿ êîòîðûå ñèëüíî ãíîÿòñÿ è îñòàâëÿþò ãëóáîêèå øðàìû.

Ñäàíû àíàëèçû ãíîÿ è íà demodex, 5 ðàç â ðàçíûõ ëàá-ðèÿõ. Ïîäòâåðäèëñÿ ñòàôèëîêîê åïèäåðìèñ.

Ïðîéäåííûå èññëåäîâàíèÿ â ñïåöèàëèçèðîâàíûõ ëàá-ðèÿõ:
1. Ïðîáû ïå÷åíè, ñàõàð, àíàëèçû ìî÷è, êàëà (â ò.÷. êàïðîãðàììó 2 ðàçà) – âñå â íîðìå
2. Àíàëèçû êðîâè ïîêàçàëè ïîâûøåííûå ëåéêîöèòû (íàëè÷èå èíôåêöèè) è áûëè ñäàíû ðåâìîïðîáû, êîòîðûå îêàçàëèñü íà ìàêñèìàëüíûõ óðîâíÿõ íîðìû. Ïîýòîìó îáñëåäîâàëñÿ ó îòîëàðèíãîëîãà è íàéäåí òîíçèëèò è ðåêîìåíäîâàíà îïåðàöèÿ óäàëåíèÿ ãëàíä, êàê ïîñòîÿííîãî èñòî÷íèêà èíôåêöèè. Îïåðàöèÿ áûëà ñäåëàíà â äåêàáðå 2004.
3. Ñäàíà èììóííîãðàììà:
table1.gif
!!! Íèêòî (â ò.÷. èìóíîëîãè) íå ñìîã ìíå ñêàçàòü êîíêðåòíî ÷òî ïîêàçûâàåò ýòà èììóííîãðàììà è åñëè ýòè äàííûå êàê-òî ñîïðèêàñàþòñÿ ñ íàøåé ïðîáëåìîé!!!
4. Äàëåå, ýíäîêðèíîëîã è ãîðìîíîãðàììà:
table2.gif
È íàðÿäó ñ äðóãèìè ìåëêèìè àíàëèçàìè ýòè áûëè âñå èññëåäîâàíèÿ.

Ïðîéäåííîå ËÅ×ÅÍÈÅ:
1. Äî ýòîé îïåðàöèè ãëàíä, ïî ðåêîìåíäàöèè äåðìàòîëîãà, ìîé ñûí ïðîøåë 3 êóðñà àíòèáèîòèêîâ doxyciclin, cefazolin, ciprofloxacin íà áàçå àíòèáèîòèêîãðàììû + Licopid, è âíåøíå: ðàçíûå àíòèáèîòè÷åñêèå ìàçè âïåðåìåøêó ñ èõòèîëîì íà íî÷ü, «áîëòóøêó» ïî óòðàì, äíåì – ìàñêè â ìåäêîñìåòîëîãèè, îáðàáîòêà æèäêèì àçîòîì è êàêîé-òî ëàìïîé ïî ëèöó + äèåòà, âèòàìèíû, è ïð. À òàêæå ïðèãîòîâëåííûå ìàçè â àïòåêàõ (ñìåñü: lincomicin, Rivanoli, Pasta Lassara) è äð. ÐÅÇÓËÜÒÀÒΠ– ÍÅÒ. Äðóãîé âðà÷ ñäåëàë âàêöèíó èç âûäåëåíèé ïðûùåé – íå áûëî ýôôåêòà! Áûëî ïðåäëîæåíî ñäåëàòü ÓÔÎ êðîâè, íî âðà÷ ôèçèîòåðàïåâòè÷åñêîãî îòäåëåíèÿ íå ðåêîìåíäóåò äåòÿì äî 18 ëåò ýòó ïðîöåäóðó. Áûëî òàêæå ïðåäëîæåíî ñäåëàòü îáðàáîòêó êðîâè îçîíîì – ñäåñü ÿ îòêàçàëñÿ ò.ê. ñ÷èòàþ ýòó ïðîöåäóðó íåóìåñòíîé â äàííîé ñèòóàöèè. À òàêæå ïåðåëèâàíèå êðîâè – ãäå ìíåíèÿ âðà÷åé ÿâíî áûëè ïðîòèâîïîëîæíûìè. Òàêæå áûë ïðåäëæåí Roacutan – íî ïðåäóïðåæäàëè ÷òî îí î÷åíü âðåäíûé.

2. Ñäåëàëè îïåðàöèþ ãëàíä è ïîìåíÿëè âðà÷åé è êëèíèêó. Íà÷÷àëè ëå÷åíèå êàïåëüíèöàìè : Ìåòðîãèë, Âèò Ñ, è íàòðèé õëîðèä. + ñïèðóëèí è àáñîðáåíòû (ïîëèôåïàí) è ïð. Âíåøíå ìàçè: Öèíêîâàÿ, Ñòðåïòîöèäîâàÿ, Èõòèîëîâàÿ è îäèí àíòèáèîòèêîâ (cefazolin, rifampicin,) ñìåøàííûå 1:1:1:1. Ñìåñü ñ rifampicin áûëà ýôôåêòèâíåé. Íåêîòîðûé ñïàä ãíîéíûõ îáðàçîâàíèé íàáëþäàåòñÿ – íî è âðà÷è áîÿòñÿ ÷òî ýòî âðåìåííî.

3. Ñåé÷àñ êàïåëüíèöû ïîçàäè è äåëàåì àíòèñòàôèëîêîêîâûé èìóíîãëîáóëëèí ÷åðåç äåíü, 10 èíúåêöèé. À òàêæå áûë ïðåäëîæåí ïðåïàðàò ÀÍÄÐÎÊÓÐ, ò.ê. âñå óòâåðæäàëè ÷òî Àêíåÿ èç-çà ïîâûøåííîãî Òåñòîñòåðîíà. Íî áûëà ñäåëàíà ãîðìîíîãðàììà è îêàçàëîñü îáðàòíîå – êàê âèäèòå ãîðìîíîãðàììà óêàçûâàåò íà ïîâûøåííûé óðîâåíü ãîðìîíîâ íàäïî÷å÷íèêà. Òåïåðü ýíäîêðèíîëîã óòâåðæäàåò ÷òî Acneea èç-çà ïîâûøåííîãî óðîâíÿ ãîðìîíîâ íàäïî÷å÷íèêà è ñëåäóåò ïðèíèìàòü OMNADREN/SUSTANON (Òåñòîñòåðîí) ÷òîáû óìåíüøèòü èõ è óâåëè÷èòü óðîâåíü òåñòîñòåðîíà!!! ß ïðî÷èòàë èíñòðóêöèþ, ãäå ïðåïàðàò íå ðåêîìåíäóåòñÿ â ïåðèîäå ïîëîâîãî ñîçðåâàíèÿ è ÷òî ìîãóò ïîÿâèòñÿ ïðûùè!!!. À òàêæå ÍÅ íàïèñàíî è íåëüçÿ íèêàê ïîíÿòü åñëè åãî ïðèìåíåíèå íå ïðèâåäåò ê äèñôóíêöèè âûäåëåíèÿ òåñòîñòåðîíà â áóäóùåì!!!

Òåïåðü, ïðîñÿ èçâåíåíèé çà ñòîëü äåòàëüíîå îáúÿñíåíèå ïðîáëåìû, íî êîòîðîå, ÿ íàäåþñü ïîìîæåò Âàì îòâåòèòü íà ìîè 3 âîïðîñà:
1. ×òî ìû óïóñòèëè â ëå÷åíèè?
2. Êàêîâà Âàøà ïðàêòèêà â ëå÷åíèè ýòîé áîëåçíè? Äîëæíû æå áûòü êàêèå-òî áîëåå ñîâðåìåííûå ñïîñîáû? (èëè ìåäèöèíà òàê óøëà âïåðåä, ÷òî çàáûëà íàøå çäîðîâüå ! )
3. ×òî âû ðåêîìåíäóåòå ïî ïîâîäó OMNADREN/SUSTANON?
Èçîáðàæåíèÿ
Òèï ôàéëà: gif table1.gif (25.0 Êá, 81 ïðîñìîòðîâ)
Òèï ôàéëà: gif table2.gif (8.8 Êá, 80 ïðîñìîòðîâ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 31.01.2005, 21:17
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,508
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,708 ðàç(à) çà 32,781 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
1\ òåñòîñòåðîí( îìíîäðåí, ñóñòàíîí) íå èñïîëüçóåòñÿ äëÿ ëå÷åíèÿ þíîøåñêèõ óãðåé.
2\êîðòèçîë íå èññëåäóåòñÿ îäíîêðàòíî, â òîì ñëó÷àå, êîãäà èùåóò íåêîå çàáîëåâàíèå, ïðè êîòîðîì åñòü ìíîãî- ìíîãî äðóãèõ ñèìïòîìîâ, ïîìèìî àêíå, êîðòèçîë èññëåäóþò â ñòóòî÷íîé ìî÷å èëè ïðîâîäÿò äåêñàìåòàçîíîâóþ ïðîáó( íåîáõîäèìîñòü â òàêîâîì èññëåäîâàíàè èîâçíèêàåò ðàçâå ÷òî ó îäíîãî èç ñîòåí òûñÿ÷ ìàëü÷èêîâ ñ óãðÿìè).
3\ þíîøåñêèå óãðè- ðàñïðîñòðàííåíîå çàáîëåâàíèå, è íàâûêè åãî íîðìàëüíîãî ëå÷åíèÿ âõîäÿò â êâàëèôèêàöèîííóþ õàðàêòåðèñòèêó äåðìàòîëîãà.
4\ óðîâíè ãîðìîíîâ ó ìàëü÷èêà â íîðìå.
5\ ãäå Âû æèâåòå è ëå÷èòåñü ?
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 31.01.2005, 21:21
Àâàòàð äëÿ doctor101
doctor101 doctor101 âíå ôîðóìà
ÂÐÀ× êîíñóëüòàíò
      
 
Ðåãèñòðàöèÿ: 24.07.2004
Ãîðîä: ISRAEL.HAIFA
Ñîîáùåíèé: 19,735
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 4,539 ðàç(à) çà 4,422 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
doctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
// Òàêæå áûë ïðåäëæåí Roacutan – íî ïðåäóïðåæäàëè ÷òî îí î÷åíü âðåäíûé.//

Ïðåïàðàòîì "ïåðâîé ëèíèè" â ñèñòåìíîì ëå÷åíèè ëå÷åíèè ACNE VULGARIS ÿâëÿåòñÿ ìèíîöèí/ìèíîöèêëèí 50ìã*2 â òå÷åíèè 2-3 ìåñÿöåâ ñ ìåñòíûì ïðèìåíåíèåì OXY5% èëè äðóãèìè ìàçÿìè.
Oäíàêî ñóäÿ ïî âñåìó â äàííîì ñëó÷àå èìååò ìåñòî CYSTIC ACNE è ïîýòîìó ïðàâîìåðíà ðåêîìåíäàöèÿ ëå÷åíèÿ ROACUTANîì.
Ëå÷åíè ìîæíî íà÷èíàòü ïðè óñëîâèè îòñóòñòâèÿ íàðóøåíèÿ ôóíêöèè ïå÷åíè/íåîáõîäèì àíàëèç êðîâè/.Ëå÷åíèå ïðîäîëæàåòñÿ 5-6 ìåñÿöåâ ñ åæåìåñÿ÷íûì áèîõèìè÷åñêèì êîíòðîëåì ôóíêöèè ïå÷åíè.
__________________
doctor Ðolonsky
israel
Ñíèìêè ñìîòðþ òîëüêî â ïðÿìîì ïîêàçå.,áåç íåîáõîäèìîñòè ñêà÷èâàíèÿ.
Ïðîñüáà ïîêàçûâàòü ñíèìêè â ïðàâèëüíîì ïîëîæåíèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 01.02.2005, 22:38
Kostea Kostea âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2004
Ñîîáùåíèé: 6
Kostea *
Áîëüøîå ñïàñèáî çà âàøå ñîó÷àñòèå â ðåøåíèè íàøåé ïðîáëåìû è âàøè èíäèêàöèè! Íî ÿ õî÷ó óòî÷íèòü 3-é âîïðîñ, ïîñêîëüêó ÿ ïîíèìàþ ÷òî Omnadren íå ëå÷èò óãðè: ÍÎ, ýíäîêðèíîëîã íàñòàèâàåò íà Omnadren, ò.ê. ó ñûíà ïîíèæåííûé óðîâåíü òåñòîñòåðîíà è ïîâûøåííûé Êîðòèçîë è Åñòðàäèîë. Ýíäîêðèíîëîã òàêæå çàìåòèë ÷òî ìû êîãäà-òî ðàíåå èñïîëüçîâàëè dexametazon â ëå÷åíèè. Äà! Íàì ïóëüìîíîëîã íàçíà÷èë dexametazon 2 ãîäà íàçàä ïðè ëå÷åíèè ïíåâìîíèè! Âû äîëæíû çíàòü äåéñòâèå dexametazonà! Òåïåðü âîïðîñ:
1. Åñòü ëè ñìûñë â ïðèìåíåíèè Omnadren ÷òîáû èíõèáèðîâàòü ïîâûøåííóþ ñåêðåöèþ ãîðìîíîâ íàäïî÷å÷íèêà?
2. Íå ïðèâåäåò ëè ïðèìåíåíèå Omnadren ê äèñôóíêöèè âûäåëåíèÿ òåñòîñòåðîíà â áóäóùåì?
3. Ïðàêòèêà ïðèåìà àíòèñòàôèëîêîêîâîãî èìóíîãëîáóëëèíà (3ìë/÷åðåç äåíü – 10 èíúåêöèé) ÿâëÿåòñÿ íîðìàëüíîé?

Î ñûíå: 15 ëåò; ðîñò 185 ñì; äî îïåðàöèè – 78 êã. Ïîñëå – 68 êã. Ïîñëåäíèé òåìï ðîñòà: 2003-2004 ã.ã – 14ñì, è 2004-2005 – 2 ñì. (Òàêæå çíàþ ÷òî Omnadren îñòàíàâëèâàåò òåìï ðîñòà – íàâñåãäà ëè ýòî?

Îòâåò íà âîïðîñ ïðîôåññîðà Ã.À. Ìåëüíè÷åíêî - Ìû ëå÷èìñÿ ñëèøêîì äàëåêî îò Ìîñêâû. Ïî÷åìó ñïðàøèâàåòå?
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 02.02.2005, 04:38
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,508
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,708 ðàç(à) çà 32,781 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìàëü÷èêó 15 ëåò, óðîâåíü òåñòîñòåðîíà íîðìàëåí, íèêòî è íèêîãäà íå ëå÷èò òåñòîñòåðîíîì óãðè, îïðåäåëåíèå óðîâíÿ òåñòîñòåðîíà, åñëè îíî óæ âîëíóåò äîêòîðà, òðåáóåò òðåõêðàòíîãî çàáîðàò êðîâè è èññëåäîâàíàèÿ îíîãî â àëèêâîòå èç òðåõ ïðîá, îäíîêðàòíûé óðîâåíü êîðòèçîëà íåèíôîðìàòèâåí..
Ïðàâäà, è ïî÷åìó ÿ ñïðàøèâàþ, ãäå Âû æèâåòå..
È,÷òî åùå âàæíåå. ïî÷åìó Âû ïðîäîëæàåòåò íàñòàèâàòü íà ïðèåìå îìíîäðåíà, âìåñòî òîãî, ÷òîáû ïîçíàêîìèòü ýíäîêðèíîëîãà ñ ìíåíèåì êîíñóëüòàíòîâ- êàê - íèêàê,â íãàøèõ êîíñóëüòàöèÿõ ñìûñë åñòü.
Ïî÷åìó Âàì òàê íðàâèòñÿ èäåÿ ëå÷åíèÿ îìíîäðåíîì ?
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 02.02.2005, 15:45
Kostea Kostea âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2004
Ñîîáùåíèé: 6
Kostea *
Óâàæàåìûé ã-í Ìåëüíè÷åíêî,
 òîì-òî è âñå äåëî, ÷òî èäåÿ ëå÷åíèÿ îìíîäðåíîì ìíå íå íðàâèòñÿ (àáñîëþòíî ïðîòèâ âòîðæåíèÿ â àíàëû ÷åëîâå÷åñêîãî îðãàíèçìà, òåì áîëåå âî âðåìÿ åãî ðîñòà) è ÿ õîòåë óáåäèòüñÿ â ïðàâèëüíîñòè ðåøåíèÿ, è â ýòîì Âû ìíå ïîìîãëè – áîëüøîå ñïàñèáî!
Ïðîñòî ðàçãîâîð øåë íè î ëå÷åíèè óãðåé îìíîäðåíîì, à î ëå÷åíèè ïîâûøåííîé ñåêðåöèè ãîðìîíîâ íàäïî÷å÷íèêà!
Èçâåíèòå çà ìîé îòâåò î ïðîæèâàíèè – Âû ìåíÿ íå òàê ïîíÿëè (â ýòîì è åñòü íåäîñòàòêè ïåðåïèñêè)! – Åñëè áû ìû áûëè â Ìîñêâå èëè ãäå-òî ðÿäîì – ÿ áû íå ðåøàë ýòè ïðîáëåìû ïî èíòåðíåòó, à ëè÷íî ñ Âàìè. À òàê êàê ìû æèâåì â Êèøèíåâå è íåò âîçìîæíîñòåé ê Âàì ïðèåõàòü, ïðîáëåìà ðåøàåòñÿ êàê Âû âèäèòå!

3. Ïðàêòèêà ïðèåìà àíòèñòàôèëîêîêîâîãî èìóíîãëîáóëëèíà (3ìë/÷åðåç äåíü – 10 èíúåêöèé) ÿâëÿåòñÿ íîðìàëüíîé äëÿ ëå÷åíèÿ?

Cïàñèáî!
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 02.02.2005, 16:41
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,508
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,708 ðàç(à) çà 32,781 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Åùå ðàç - êðàéíå ðåäêî ñóùåñòâåò ñèòóàöèÿ, êîãäà ïðè÷èíîé àêíå ( íî â ýòîì ñëó÷àå ñ àêíå ñðîñóùåñòâóåò åùå äâà -òðè äåñÿòêà ïðîáëåì) ÿâëÿåòñÿ íàðóøåíèå äåÿòåëüíîñòè íàäïî÷å÷èíêîâ. Ïðè ýòîì ÍÅ ñìîòðÿò èçîëèðîâàííî êîðòèçîë ( ó çäîðîâîãî ÷åëîâåêà ïðîñòî îò òîãî, ÷òî ê íåìó â âåíó èãëîé âõîäÿò. êîðòèçîë ïîâûøàåòñÿ). Åñëè èùóò íåêèå ïðîáëåìû, ñâÿçàííûå ñ êîðòèçîëîì. òî ñìîòðÿò ñîâñåì äðóãèå ïîêàçàòåëè.
Åùå ðàç - þíîøåñêèå óãðè ÍÅ âûçûâàþòñÿ íåõâàòêîé òåñòîñòåðîíà èëè ïðîáëåìàìè ñ ýñòðàäèîëîì, ýòè ïàðàìåòðû ÍÅÒ íåîáõîäèìîñòè ñìîòðåòü ïðè óãðÿõ, êîðòèçîë, åñëè è íóæíî ñìîòðåòü, òî íå îäíîêðàòíûé èç âåíû, îìíîäðåí íå âëèÿåò íà êîðòèçîë.. Ñëîâîì, ÿ îçâåðåëà ..
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 02.02.2005, 18:10
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,508
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,708 ðàç(à) çà 32,781 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âî èçáåæàíèå ìåæäóíàðîäíûõ êîíôëèêòîâ :Âàø âðà÷ ìîæåò áåç òðóäà ïîëó÷èòü èíôîðìàöèþ ïî ëå÷åíèþ àêíå ñ ïîìîùüþ ñèìòåìû ìåäëàéí. Íàéäÿ â ïîèñêîâèêå Pubmed ïî êëþ÷åâûì ñëîâàì acne vulgaris & young men 4 ññûëêè ( ïðèâîæó îäíó èç íèõ )

: J Dermatol. 2001 Jan;28(1):1-4. Related Articles, Links


Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris.

Parsad D, Pandhi R, Nagpal R, Negi KS.

Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Acne vulgaris is a common skin disease seen primarily in adolescent and young adults. As the treatment involves long term therapy with antibiotics, an agent with a long half life can be very useful in increasing the compliance. To evaluate the role of a monthly dose of azithromycin and compare it with daily doxycycline, we conducted this randomized comparative study. Sixty patients with moderate to severe acne were randomly assigned to two treatment groups, A & B. Patients in group A received 100 mg doxycycline daily in addition to topical 0.05% tretinoin cream, whereas patients in group B were given 500 mg azithromycin once a day for four days per month along with 0.05% topical tretinoin for a total of 12 weeks. Of the 60 patients, 22 in group A and 28 in group B were evaluated. The monthly dose of azithromycin was found to be as effective as daily doxycycline on a pure protocol basis and statistically significantly better than doxycycline by intention to treat analysis.
( Ýòà ññûëêà âûñîêîãî óðîâíÿ- èññëåäîâàíèå ñ âûñîêèì óðîâíåì äîêàçàòåëüíîñòè )

Publication Types:
Clinical Trial
Randomized Controlled Trial

PMID: 11280457 [PubMed - indexed for MEDLINE]

--------------------------------------------------------------------------------
âðà÷ ñìîæåò ïðîäîëæèòü çíàêîìñòâî ïî äðóãèì ññûëêàì. Âóëüãàðíûå óãðè- òðóäíàÿ, íî ðåøàåìàÿ ÷åëîâå÷åñòâîì áåç ïðèâëå÷åíèÿ îìíîäðåíà ïðîáëåìà.
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 02.02.2005, 21:42
EVP EVP âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 08.07.2004
Ãîðîä: Êèðîâ
Ñîîáùåíèé: 7,190
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 992 ðàç(à) çà 975 ñîîáùåíèé
EVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Use of Systemic Agents in the Treatment of Acne Vulgaris
BETTY ANNE JOHNSON, M.D., PH.D., and JULIA R. NUNLEY, M.D. Virginia Commonwealth University Medical College of Virginia School of Medicine, Richmond, Virginia

Systemic Therapy for Acne

Oral Antibiotics

Although topical therapy is generally adequate for comedonal acne, control of inflammatory acne usually requires systemic antibiotics. The antibiotics that have proved to be most effective include tetracycline, doxycycline (Vibramycin), minocycline (Minocin) and erythromycin. These drugs penetrate the follicle and sebaceous gland well and decrease colonization by P. acnes. They also have an anti-inflammatory effect independent of their antimicrobial properties. Although rare hypersensitivity reactions have been reported, the safety profile of these antibiotics is, in general, excellent, making routine laboratory monitoring in the asymptomatic, healthy patient unnecessary.1,2 Prescription guidelines for these antibiotics, as well as a detailed list of adverse reactions, are found in Tables 2 and 3.

Tetracycline is extremely inexpensive but may cause adverse effects, including vaginal yeast infections and dyspepsia (rarely, esophagitis with esophageal ulcerations). Other rare adverse effects include photosensitivity and pseudotumor cerebri. It is unclear whether tetracycline interferes with oral contraceptive efficacy and, therefore, young women are often counseled to use a back-up method of contraception while taking tetracycline.3 Tetracycline may cause discoloration of forming teeth and should not be given to pregnant women or to children younger than 13 years unless all permanent teeth have erupted. Although the tetracyclines have a long track record of safety, instances of single-organ dysfunction (most commonly, severe cutaneous reaction) have been reported, as well as a few cases of hypersensitivity reaction and serum sickness*like reaction2 (Table 3). Tetracycline therapy should be avoided in patients with renal or hepatic disease.

Doxycycline is a tetracycline derivative that exhibits excellent penetration into follicles and sebaceous glands. It is better tolerated than tetracycline and may be taken with food. Of the tetracycline derivatives, it is the one most likely to cause photosensitivity. Other adverse effects are similar to those of tetracycline.

Minocycline is considered the most effective of the tetracycline derivatives, possibly because preexisting minocycline resistance is rare.4 It can be taken with food and, unlike the other tetracyclines, only infrequently causes photosensitivity. Most adverse effects of minocycline are similar to those of the other tetracyclines (Table 3). However, minocycline may cause cutaneous hyperpigmentation in scars, vertigo and, in rare instances, the development of a lupus-like syndrome. Minocycline is also associated with a higher frequency of hypersensitivity reactions than the other tetracyclines. Although hyperpigmentation is slow to fade, the other reactions usually resolve promptly with discontinuation of therapy.

Erythromycin is inexpensive but often causes dyspepsia or abdominal discomfort even when taken with meals. It is considered safe for use during pregnancy. However, P. acnes resistance to erythromycin develops more frequently (in as many as 60 percent of isolates) than with the other systemic antibiotics.
If treatment fails despite compliance with systemic antibiotic therapy, two clinical entities must be considered: antibiotic resistance and folliculitis related to overgrowth of gram-negative Enterobacteriaceae, Staphylococci or Malassezia yeasts.4 Aerobic and anaerobic cultures and sensitivity determinations should be used to decide on appropriate antibiotics. Gram-negative folliculitis is frequently treated with ampicillin, less commonly with trimethoprim-sulfamethoxazole (Bactrim, Septra) and, occasionally, with isotretinoin.5,6 The addition of topical benzoyl peroxide, a broad-spectrum antimicrobial agent, may also be beneficial in many patients who have folliculitis related to either bacteria or yeast.4
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 02.02.2005, 21:45
EVP EVP âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 08.07.2004
Ãîðîä: Êèðîâ
Ñîîáùåíèé: 7,190
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 992 ðàç(à) çà 975 ñîîáùåíèé
EVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEVP ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Isotretinoin

Nodulocystic acne, if left untreated, may cause physical and emotional scarring. This form of acne is unlikely to respond to topical therapy. Initially, patients should be prescribed an oral antibiotic. If the acne fails to respond after six months of conventional therapy, treatment with isotretinoin should be considered.6
Isotretinoin is an oral retinoid preparation that decreases the size and secretion of the sebaceous glands, normalizes follicular keratinization, inhibits P. acnes growth and exerts an anti-inflammatory effect.15 Isotretinoin is labeled for use in patients with nodulocystic acne and can markedly improve this condition in most persons. There is a growing international consensus that, although the primary indication for isotretinoin is nodulocystic acne, patients who have an inadequate response to appropriate conventional therapy for less severe acne may also benefit from this drug.16 Patients who have scarring inflammatory acne and those with acne that causes severe psychologic distress may also be candidates.6,16 However, isotretinoin is FDA*labeled only for treatment of severe recalcitrant nodular acne.17
The typical dosage of isotretinoin is 0.5 to 1 mg per kg daily in two divided doses, with a standard cumulative maximum of 120 to 150 mg per kg per treatment course.6,15,16,18,19 Because the intensity of the side effects of isotretinoin is dose-related, the lower dosage may be chosen. However, dosages of 0.5 mg per kg daily or less are more frequently associated with treatment failure.16,20 Initiation of isotretinoin therapy may cause a marked flare-up of the patient's acne. It is, therefore, common practice to introduce the medication slowly, beginning at 0.1 to 0.5 mg per kg daily, and increasing to the desired dosage of 1 mg per kg daily by the end of the first month of treatment.6,15 The average duration of therapy is five months, at which time most patients will have reached the desired goal of 120 to 150 mg per kg. However, a longer course of therapy is necessary in patients taking lower initial or daily dosages.
Adjuvant therapy with other agents may be considered during isotretinoin treatment. Topical antibiotics may be beneficial, but use of topical keratolytics and drying agents should be discontinued because concomitant use may lead to extensive dryness. Occasionally, oral erythromycin or prednisone is used at the beginning of isotretinoin therapy to control the initial acne flare-up. None of the tetracyclines should be used for this purpose because the combination of a tetracycline and isotretinoin increases the likelihood of pseudotumor cerebri development.20
Pustules generally clear more rapidly than papules or nodules. Lesions on the face, upper arms and legs tend to respond more quickly than those on the trunk. After reaching the goal dosage of 120 to 150 mg per kg, isotretinoin therapy should be discontinued even if the acne is not completely clear because improvement continues for one to two months following cessation of treatment.
In a study of patients who were observed for 10 years, a single course of isotretinoin therapy completely cleared acne in more than 60 percent.16 If relapse occurred, it usually developed within the first three years after isotretinoin therapy; 78 percent of relapses were reported to occur within the first 18 months.16 Of the 39 percent of patients who experienced a relapse, 16 percent required re-initiation of oral antibiotics, and 23 percent required additional isotretinoin therapy.16 In those who relapse, repeated full courses of isotretinoin may be required. Of the 23 percent of patients who required repeated courses in one study, 17 percent had two courses, 5 percent had three courses and 1 percent had four to five courses, with predictably successful results and without additional adverse reactions.21
The side effect profile of isotretinoin is extensive, and physicians prescribing this medication should be well-versed in its potentially dangerous consequences. Patients should be evaluated every four weeks for adverse effects and to ensure compliance with therapy.18 A reduction in dosage or cessation of therapy usually causes fairly rapid resolution of clinical and laboratory side effects.
Mucocutaneous reactions are the most common adverse effects.19 Drying of the mucosal surfaces occurs in nearly all users, with cheilitis being the most common finding. Frequent application of moisturizing agents is necessary. Many patients who wear contact lenses are forced to switch to eyeglasses during the course of therapy because of conjunctival dryness. Reddening of the skin and increased photosensitivity vary among different populations.19
More serious adverse effects are rare, and most involve the musculoskeletal system.19 Arthralgias and muscle stiffness occur more frequently in those who participate in vigorous exercise. Long-term retinoid therapy may be complicated by skeletal changes, including osteoporosis and osteophyte formation. However, no studies have reported notable bony changes associated with short-term isotretinoin therapy for the treatment of acne. Mild to moderate headaches are fairly common; if the headache is severe or associated with visual changes, the patient should be evaluated for the presence of pseudotumor cerebri, a rare consequence of therapy. Patients may complain of fatigue or mild mood alterations and, rarely, isotretinoin may precipitate a depression. There have been reports of patients committing suicide while taking isotretinoin, and patients at risk should be monitored carefully.22

REFERENCES

Driscoll MS, Rothe MJ, Abrahamian L, Grant-Kels JM. Long-term oral antibiotics for acne: is laboratory monitoring necessary? J Am Acad Dermatol 1993;28:595-602.
Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224-30.
Miller DM, Helms SE, Brodell RT. A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 1994;30: 1008-11.
Eady EA. Bacterial resistance in acne. Dermatology 1998;196:59-66.
Ortonne JP. Oral isotretinoin treatment policy. Do we all agree? Dermatology 1997;195(suppl 1):34-7.
Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997;194:351-7.
Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl 1990;152:21-4.
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
Redmond GP. Effectiveness of oral contraceptives in the treatment of acne. Contraception 1998;58: 29S-33S.
Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997;136:66-70.
Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des 1999;5:707-23.
Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998;196:148-52.
Schmidt JB. Other antiandrogens. Dermatology 1998;196:153-57.
Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatol Clin 1996;14:803-11.
Leyden JJ. The role of isotretinoin in the treatment of acne: personal observations. J Am Acad Dermatol 1998;39:45-8.
Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993;129: 292-6.
Accutane prescribing information. Nutley, N.J.: Roche Pharmaceuticals, 1998.
Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhea and acne. Dermatology 1998;196:140-7.
Meigel WN. How safe is oral isotretinoin? Dermatology 1997;195(suppl 1):22-8.
Wolverton SE. Retinoids. In: Wolverton SE, Wilkin JK, eds. Systemic drugs for skin diseases. Philadelphia: Saunders, 1991:187-218.
Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993;129:297-301.
Lamberg L. Acne drug depression warnings higlight need for expert care [News]. JAMA 1998; 279:1057.
Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy.
N Engl J Med 1985;313:837-41.
Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995;333:101-6.
Shear NH. Oral isotretinoin: prescribers beware [Editorial]. CMAJ 1999;160:1723-4.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 21:36.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.